This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with
severe polycystic liver disease who are not candidates or decline surgical treatments such as
liver cyst fenestration, liver resection or liver transplantation. A total of 42 patients
will be recruited -14 who will receive placebo and 28 the study drug. Preliminary evidence
indicates that this drug is safe and non-toxic in other disease states. Treatment with this
drug holds promise not only for individuals with liver involvement, but also for many more
patients with polycystic kidney disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Center for Research Resources (NCRR) Novartis